Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
November 04, 2020 12:15 ET
|
Fortress Biotech, Inc.
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners
October 19, 2020 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
September 14, 2020 08:00 ET
|
Fortress Biotech, Inc.
- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies - Phase 2 study met primary objective, supporting initiation of two parallel Phase 3...
Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences
September 10, 2020 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
August 28, 2020 08:30 ET
|
Fortress Biotech, Inc.
Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Control,...
Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management
August 28, 2020 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
August 26, 2020 20:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today...
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020
August 12, 2020 07:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 10, 2020 16:30 ET
|
Fortress Biotech, Inc.
Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columbia University to develop novel oligonucleotide platform for the treatment...
Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
July 31, 2020 07:30 ET
|
Fortress Biotech, Inc.
NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing...